Wellesley will host the eighth annual Plunge for Elodie raises money to benefit research programs for Epidermolysis bullosa, a rare skin disease.

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis; ...

Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation. Read why KRYS ...

FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) ...

Dilgen, a 22-year-old Tottenville resident, has been battling epidermolysis bullosa (EB), a rare, life-threatening genetic ...

Q4 2024 Earnings Call Transcript March 20, 2025 Abeona Therapeutics Inc. beats earnings expectations. Reported EPS is $-0.24, ...

This is the eighth year for these plunges at 21 locations in six different countries. Brooks is the 5-year-old son of former Barboursville residents Brian and Annie Keys Kendrick, and the grandson of ...

Carol Schober-Flores, BSN, RN, is a Mohs Surgical Nurse and Epidermolysis Bullosa Nurse Specialist, University Hospital, Denver, CO. Topical ointments can be applied directly over the Mepitel ...

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) in a report released on Monday morning, Marketbeat.com reports. The firm currently has a $15.00 ...

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) from a sell rating to a hold rating in a report published on Monday morning. Other equities research analysts also ...

FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 Launch preparations on track toward goal ...

Alliance Global Partners raised the firm’s price target on Abeona Therapeutics (ABEO) to $25 from $20 and keeps a Buy rating on the shares ...